Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)



Status:Completed
Conditions:Renal Impairment / Chronic Kidney Disease, Diabetes
Therapuetic Areas:Endocrinology, Nephrology / Urology
Healthy:No
Age Range:30 - 70
Updated:8/9/2017
Start Date:July 2016
End Date:August 2017

Use our guide to learn which trials are right for you!

A Phase II, Open-label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease

A Phase II, Open-Label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in
Patients With Type 2 Diabetes and Chronic Kidney Disease (RMTX-CL001). NKA is made from
expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. All
enrolled subjects will be treated with up to two injections of NKA at least 6 months apart.

A Phase II, Open-Label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in
Patients With Type 2 Diabetes and Chronic Kidney Disease (RMTX-CL001). This is a
Multi-center, prospective, open-label, single-group study. NKA is made from expanded
autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To
manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX,
LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin
based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and
shipped to the clinical site for use. All enrolled subjects will be treated with up to two
injections of NKA at least 6 months apart. Up to 30 subjects undergoing NKA injection will be
enrolled into the study. Patients who have received a single injection of NKA under previous
research protocols may enroll in this clinical trial to receive a single additional
implantation. Patients who have never received an NKA injection may enroll in this clinical
trial for up to a total of two (2) NKA injections, temporally spaced at least 6 months apart.
All biopsies are to be taken from a single kidney, and all NKA injections are to be given
into the kidney that was biopsied.

Patients who complete screening procedures satisfying all I/E criteria will be enrolled into
the study immediately prior to the injection. Patients who do not meet all criteria before
injection will be considered screen failures. Once a patient has been injected, the patient
will have completed treatment and every effort should be made to ensure the patient completes
all follow-up visits. Injection dates for the first 3 patients receiving their second NKA
injection will be staggered by a minimum of 3 week intervals to allow for assessment of acute
adverse events and other safety parameters by a Data Safety Monitoring Board (DSMB). At the
completion of the follow-up visits, patients will continue in a long-term observational
follow-up period. Patients will be followed for a total of 36 months following the last NKA
injection under this protocol, whether the first or second injection.

Inclusion Criteria:

1. Males and females, age 30 - 70 years.

2. Patients with type 2 diabetes mellitus (T2DM).

3. Patients with diabetic nephropathy as the underlying cause of their renal disease.

4. If not previously implanted with NKA, CKD defined as a GFR of 20 - 50 mL/min/1.73m2
inclusive. Ifs previously treated with a single NKA implantation, eGFR 15 to 60 mL/min
may also enroll.

5. Microalbuminuria (urinary albumin-creatinine ratio (UACR) ≥ 30 mg/g or urine albumin
excretion ≥ 30 mg/day on 24 hour urine collection) not explained by an alternative
diagnosis.

6. Systolic blood pressure between 105 and 140 mmHg (inclusive) and diastolic blood
pressure ≤90 mmHg.

7. Treatment with angiotensin inhibitor (ACEI) or angiotensin blocker (ARB) initiated at
least 8 weeks prior to enrollment. Treatment must be stable for the 6 weeks prior to
implant. Patients intolerant of ACEI or ARBs may be included if stable BP is within
acceptable limits.

8. Minimum of 2 measurements of eGFR or serum creatinine (sCr) at least 3 months apart
and within 12 months before Screening, to define the rate of progression of CKD.

9. Willing and able to refrain from use of non-steroidal drugs (NSAIDs) (including
aspirin), clopidogrel, fish oil, dipyridamole, prasugrel, or platelet inhibitors for 7
days before and after both biopsy and implant.

10. Willing and able to cooperate with all aspects of the study.

11. Willing and able to give signed informed consent.

Exclusion Criteria:

1. Type 1 diabetes mellitus (DM).

2. History of renal transplant.

3. HbA1c > 10% at Screening.

4. Hemoglobin levels < 9 g/dL prior to implant.

5. Known allergy to kanamycin or structurally similar aminoglycoside antibiotics.

6. Abnormal coagulation status as measured by partial thromboplastin time (APTT),
international normalized ratio (INR), and/or platelet count at Screening.

7. Not a good candidate for the implantation procedure (based on the assessment of the
investigator or operator) including patients who are morbidly obese, have BMI > 45,
have excessive fat surrounding the kidney, or who are otherwise at risk for serious
complications.

8. Clinically significant infection requiring parenteral antibiotics within 6 weeks of
implantation.

9. Patients with small kidneys (average size < 9 cm) or only one kidney, as assessed by
MRI or renal US within 1 year of screening.

10. Patients with acute kidney injury or a rapid decline in renal function within 3 months
prior to implantation.

11. Patients with renal tumors, polycystic kidney disease, renal cysts or other anatomic
abnormalities that would interfere with implantation procedure (e.g., cysts in the
pathway of the injection for implantation), hydronephrosis, skin infection over
proposed implantation sites, or evidence of a urinary tract infection.

12. Female subjects who are pregnant, lactating (breast feeding) or planning a pregnancy
during the course of the study, or who are of child bearing potential and not using a
highly effective method of birth control (including sexual abstinence). Subjects must
be willing to continue birth control methods throughout the course of the study.

13. History of cancer within the past 3 years (excluding non-melanoma skin cancer and
carcinoma in situ of the cervix).

14. Life expectancy of less than 2 years.

15. Any contraindication or known anaphylactic or severe systemic reaction to either human
blood products or materials of animal (bovine, porcine) origin or anesthetic agents.

16. Positive for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis
C Virus (HCV) assessed at the Screening Visit.

17. Subjects requiring treatment for tuberculosis (TB) in the past 3 years.

18. Immunocompromised subjects or patients receiving systemic immunosuppressive agents
(including patients treated for chronic glomerulonephritis) within 3 months of
implantation.

19. Subjects with uncontrolled diabetes (defined as metabolically unstable by the PI), or
with incapacitating cardiac and/or pulmonary disorders.

20. History of active alcohol and/or drug abuse that in the investigator's assessment
would impair the subject's ability to comply with the protocol.

21. Patients with elevated transaminases (ALT or AST > 3.0 x ULN) at Screening.

22. Patients with bleeding disorders that would, in the opinion of the Investigator,
interfere with the performance of study procedures; patients taking coumarins (e.g.
Warfarin) or other anticoagulants (e.g. enoxaparin or direct thrombin inhibitors).

23. Any circumstance in which the investigator deems participation in the study is not in
the subject's best interest.

24. Use of any investigational product within 3 months of the implantation without
receiving prior written consent of the Medical Monitor.
We found this trial at
1
site
Chapel Hill, North Carolina 27599
(919) 962-2211
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials